Oxford NeuroLabs (ONL), founded by leading Oxford clinicians and AI experts, is creating digital biomarkers for disease monitoring using everyday devices like phones and smartwatches, delivering 2.3x faster detection and 96% accuracy compared to current methods. The company has exclusive access to an actively growing proprietary dataset built over 9 years through £7M+ in pharmaceutical funding, creating a significant competitive advantage that cannot be replicated quickly. ONL is launching first with pharmaceutical companies (who have already funded the lab's research), before expanding into the broader healthcare market with a solution that reduces clinical trial costs by $15-20M while having industry-leading accuracy.